Context Therapeutics is trading at $0.20, up 5.29%, with the broader U.S. market rebound the likeliest context; no company-specific catalyst was identified for November 2, 2026.
- U.S. stocks rose as oil prices fell on hopes for progress in U.S.-Iran talks.
- Context Therapeutics is rising despite a biotech-sector decline, which does not explain its gain.